| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial
|
Kudo M.; Lim H.Y.; ANN-LII CHENG; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y. |
| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
|
Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG; Ducreux M. |
| 國立成功大學 |
2022 |
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
|
Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P. |
| 臺大學術典藏 |
2021-09-01T01:54:20Z |
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
|
Faivre S.; Raymond E.; Boucher E.; Douillard J.; Lim H.Y.; Kim J.S.; Zappa M.; Lanzalone S.; Lin X.; DePrimo S.; Harmon C.; Ruiz-Garcia A.; Lechuga M.J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:07Z |
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
|
Harmon C.S.; DePrimo S.E.; Raymond E.; ANN-LII CHENG; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Lechuga M.J.; Lanzalone S.; Lin X.; Faivre S. |
| 臺大學術典藏 |
2021-09-01T01:54:07Z |
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib
|
Faivre S.; Zappa M.; Vilgrain V.; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Im S.-A.; Kang Y.-K.; Bouattour M.; Dokmak S.; Dreyer C.; Sablin M.-P.; Serrate C.; ANN-LII CHENG; Lanzalone S.; Lin X.; Lechuga M.J.; Raymond E. |
| 臺大學術典藏 |
2021-09-01T01:53:51Z |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
|
Park J.-W.; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:42Z |
Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
|
ANN-LII CHENG; Amarapurkar D.; Chao Y.; Chen P.-J.; Geschwind J.-F.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; Park J.-W. |
| 臺大學術典藏 |
2021-08-31T06:29:48Z |
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
|
ANN-LII CHENG; Kang Y.-K.; He A.R.; Lim H.Y.; Ryoo B.-Y.; Hung C.-H.; Sheen I.-S.; Izumi N.; Austin T.; Wang Q.; Greenberg J.; Shiratori S.; Beckman R.A.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:46Z |
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
|
ANN-LII CHENG; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. |
